89.1 WEMU

Doctors Scrutinize Overtreatment, As Cancer Death Rates Decline

Jun 5, 2018
Originally published on June 5, 2018 6:25 pm

For many years, the death rate from cancer climbed steadily, and the focus of big cancer meetings was the quest for better treatments to bring malignancies under control. Cancer death rates have been falling in recent decades, and that's allowed researchers to ask another important question: Are some people getting too much treatment for their cancers?

The answer, from the American Society of Clinical Oncology meeting in Chicago these past few days, is an emphatic yes.

One dramatic example revealed at the meeting relates to the most common form of breast cancer, known as hormone-positive, HER-2 negative disease. For many women who have this diagnosis, but for whom the disease has not spread to lymph nodes, a new study finds that anti-hormone treatment after surgery is enough, and women won't benefit from rounds of toxic and uncomfortable chemotherapy.

Treatment of breast cancer for this large group of women will become easier. And for the many women who already choose not to undertake chemotherapy, they can be reassured that it's the right call.

Likewise, researchers from France presented evidence that people with severe colon cancer don't benefit from a common treatment, which involves heated chemotherapy administered at the time of surgery. This treatment has been in use for 15 years, without good evidence that it actually works. Some doctors were adamant about using it, while others shunned it. The study of 265 patients found that it didn't work, says Dr. Francios Quenet, at the Regional Cancer Institute on Montpellier, France.

The study is "an excellent example of how less is more," when it comes to certain cancer treatments, says Dr. Andrew Epstein, an oncologist from Memorial Sloan Kettering Cancer Center who spoke on behalf of ASCO.

Patients with advanced kidney cancer can also be spared surgery, according to another study presented at the meeting. "Based on studies that were done 20-30 years ago, the patients who had their kidneys removed lived a bit longer than the patients who did not," Dr. Bruce Johnson, the president of ASCO and a cancer doctor at the Dana Farber Cancer Institute in Boston, tells Shots. A study of 450 patients coordinated by researchers in Paris found that the surgery was pointless. Patients who had their kidneys removed did no better than those who got chemotherapy. Those who avoided surgery were spared the trauma and the expense of this operation.

The surgeon who presented the study at the meeting's giant plenary session, Arnaud Mejean, got a big cheer from the audience after he projected a cartoon at the end of his talk, showing someone shooting himself in the foot. His point was that this kind of study isn't in a surgeon's self-interest – but it should be done for the interest of patients. And he suggested that all cancer physicians should ponder what that means in their own practices.

Why are doctors giving patients challenging and unnecessary treatments?

Johnson says one reason is that the way that cancer treatments evolve. In the case of breast cancer, the chemotherapy was first developed to treat advanced cancers. There, it was used aggressively to kill as much cancer as possible. Over the years, doctors started using it for less advanced cases, and eventually as a treatment to prevent cancer from coming back (known as "adjuvant therapy.")

Doctors and patients already knew that it provided relatively little advantage for many women when used as an adjuvant – perhaps reducing the risk of cancer recurrence by just a few percentage points, for women who have a low risk on genetic tests that can help predict the odds of a recurrence. But narrowing down that risk even more required a huge study, involving 10,000 women and taking many years.

Drug companies, which fund many cancer studies, would have no interest in funding that study, so the National Institutes of Health backed it, with the help of governments overseas and advocacy organizations within the United States.

There may be many other cancer treatments that are unneeded and possibly even harmful. Many long-time medical practices are based on tradition and thin evidence. But Johnson worries the federal government has been losing interest in this kind of expensive and time-consuming research. He notes that over the past decade, the number of studies presented at the ASCO meeting that have been funded by the U.S. government has dropped from 575 to 143. "It's cut in one-fourth!" he laments. "And one of the things that we think is critically important is a robust clinical infrastructure supported by our government."

Indeed, European researchers presented many of the big studies at this year's meeting. There, governments seem to have more patience for studies that can last for a decade or more, and care about research that will save government health services the costs of unneeded treatment.

To be sure, the pharmaceutical industry is funding plenty of studies – but mostly they aim to bring expensive new drugs on the market. There was plenty of evidence of that at the meeting as well, both in lavish displays where companies brag about what they hope will soon come out of their pipelines, as well as studies showing that pricey new drugs are better than inexpensive treatments.

In the hot field of immunotherapy alone, there are more than 2,000 drugs in development, according to Dr. Solange Peters at Lausanne University Hospital in Switzerland and president-elect of the European Society for Medical Oncology. The number of possible combination therapies is mind-boggling, and it's hard to find the true winners. "Many combinations are not based on biological mechanisms and many are likely to fail," she said in a presentation.

Dr. Otis Brawley, chief medical officer of the American Cancer Society, tells NPR a glut of "me-too" drugs that don't offer meaningful advances, contributes to some of the confusion. It's left up to doctors "to figure out the drugs we should be using versus the drugs we should not be using."

"If I can use an auto industry example, if General Motors develops an SUV that means Chrysler and Ford have to develop an SUV to compete in that market, and the drug companies do the same thing, unfortunately," Brawley says.

He notes there are 30 companies producing very similar immunotherapy drugs, "and one of our concerns is they're actually slowing down the development of immunotherapy drugs by having too many drugs that are very similar out in clinical trials." These studies all are competing for patients, "and slowing down the completion of all the trials."

"This is a huge problem," Brawley says. "We sometimes wish we had a policeman who could direct traffic when it comes to drug development."

But he admits he can't figure out what that would look like, given that the profit-driven system has worked well, in that it has brought exciting drugs to market.

Copyright 2018 NPR. To see more, visit http://www.npr.org/.

MARY LOUISE KELLY, HOST:

An enormous meeting of cancer doctors wrapped up today in Chicago, and the biggest news was not about exciting new treatments but about current treatments that turn out to be all pain and no gain. NPR's Richard Harris mingled with the 40,000 or so attendees at the American Society of Clinical Oncology meeting, and he brought us back this report.

RICHARD HARRIS, BYLINE: The most notable story from the meeting was about breast cancer. A major study found that for women with the most common form of breast cancer, a round of toxic chemotherapy just to be safe actually doesn't make sense. Doctors already knew that in this group, the chemotherapy provided at best a small advantage. But Dr. Harold Burstein says they have now identified a whole bunch of women for whom it provides no benefit at all.

HAROLD BURSTEIN: You know, there's a huge difference between saying, well, you might benefit a little bit and saying there's no benefit for you.

HARRIS: Burstein, at the Dana-Farber Cancer Institute in Boston, was speaking on behalf of ASCO, the Oncology Society. The study was presented Sunday and is being published in The New England Journal of Medicine. And that wasn't the only study that found less is more when it comes to cancer treatment.

In kidney cancers that have spread throughout the body, surgeons routinely remove the diseased organ in addition to giving a patient chemotherapy. But speaking to a crowd of thousands of doctors, Arnaud Mejean from the Georges Pompidou European Hospital of Paris announced the results of a study showing that surgery didn't help kidney cancer patients and might even make matters worse. And then at the end of his talk, he disclosed his conflict of interest.

(SOUNDBITE OF ARCHIVED RECORDING)

ARNAUD MEJEAN: I am a surgeon mostly involved in kidney surgery.

HARRIS: He then flashed on the screen a cartoon character who has shot himself in the foot.

(SOUNDBITE OF ARCHIVED RECORDING)

MEJEAN: I know that it is - yes, I know nobody's perfect. Thank you for your applause.

HARRIS: But he went on to point out that doctors throughout the room should face up to the truth of their own practices even if it isn't in their own self-interest.

(SOUNDBITE OF ARCHIVED RECORDING)

MEJEAN: Thank you very much.

HARRIS: There were other studies presented at the meeting that pointed to treatments that don't work at all or to toxic medicines that are just as effective at lower doses. These studies had a common feature. They were funded primarily by governments. Dr. Bruce Johnson, president of ASCO, noted a worrying trend in this regard.

BRUCE JOHNSON: One of the things about our meeting is that a number of studies that are presented that are sponsored by the government have dropped from about 575 to 143 over the last decade. It's cut in a fourth.

HARRIS: And instead of government funding, clinical trials are mostly funded by drug companies pushing to develop new, high-priced medications. Dr. Otis Brawley, chief medical officer of the American Cancer Society, is concerned that there are now too many of these studies happening all at once, particularly for immune-boosting therapies. Most of these are very similar to what's already on the market, and drug companies are simply jockeying to get a piece of the action.

OTIS BRAWLEY: They're actually slowing down the development of immunotherapy drugs by having too many drugs that are very similar out in clinical trials.

HARRIS: Patients are a scarce resource, he notes, and it's a shame to see so many of them enrolled in studies that aren't breaking any new ground.

BRAWLEY: This is a huge problem. We sometimes wish that we had a policeman who could sort of direct traffic when it comes to drug development.

HARRIS: But Brawley admits that it would be tough to figure out a way to make that happen. Richard Harris, NPR News. Transcript provided by NPR, Copyright NPR.